Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Oliver & Co who wrote (3733)	2/4/1998 12:27:00 PM
From: tnsaf	Read Replies (2) of 6136

Here is an excerpt from the latest Medscape mailing. It is long and gives some history and comparison of HIV treatments. Jason o AIDS________________________________________________________ <http://www.medscape.com/Medscape/public/MP/98/0130.html#01> - Impact of HIV-1 Protease Inhibitors On the Cost of Treating HIV/AIDS Patients ---------------------------------------------------------- Expensive new drug therapies may cost $15,000 per year. This price tag may boost total costs to third-party payers, but decreased utilization could offset this trend. [Drug Benefit Trends 10(1): 27-31, 1998]

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next